Melatonin (Slenyto®). HTA ID: 22048

Assessment Status Rapid Review Complete
HTA ID 22048
Drug Melatonin
Brand Slenyto®
Indication For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient.
Assessment Process
Rapid review commissioned 05/07/2022
Rapid review completed 09/08/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of prolonged release melatonin (Slenyto®) compared with the current standard of care.